title: Phase 2 trial of oral S-1 combined with low-dose cisplatin for unresectable advanced pancreatic cancer.
abstract: OBJECTIVE
  A phase 2 trial of S-1 combined with cisplatin was conducted for unresectable pancreatic cancer.
  
  
  METHODS
  S-1 was administered for 28 days followed by a rest of 14 days. Cisplatin was infused on days 1-5, 8-12, 15-19 and 22-26 of the first course. After the second course, S-1 was administered as maintenance chemotherapy.
  
  
  RESULTS
  Thirty patients were enrolled and the responses observed were 0 complete response, 5 partial response, 22 stable disease and 3 progressive disease, with an overall response rate of 17% (95% confidence internal (CI), 6-35%). Toxicity was tolerable, with grade 3 toxicities observed for leukocytopenia (10%), neutropenia (7%), anemia (3%), thrombocytopenia (3%), anorexia (13%), and nausea and vomiting (7%). The median survival time (MST) and the 1-year survival rate were 9.0 months (95% CI, 6.0-14.5 months) and 35.7% (95% CI, 19-55%), respectively.
  
  
  CONCLUSIONS
  S-1 with low-dose cisplatin is well tolerated and effective for advanced pancreatic cancer.
authors.affiliation: Second Department of Surgery, Wakayama Medical University, School of Medicine, Wakayama, Japan.
authors.forename: Shinomi
authors.initials: S
authors.lastname: Ina
authors.forename: Masaji
authors.initials: M
authors.lastname: Tani
authors.forename: Manabu
authors.initials: M
authors.lastname: Kawai
authors.forename: Seiko
authors.initials: S
authors.lastname: Hirono
authors.forename: Motoki
authors.initials: M
authors.lastname: Miyazawa
authors.forename: Ryohei
authors.initials: R
authors.lastname: Nishioka
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Fujita
authors.forename: Hiroki
authors.initials: H
authors.lastname: Yamaue